GNA Biosolutions and project partners launch new research project to develop TB diagnostic platform for POC applications

Molecular testing for tuberculosis (TB) could one day take only a few minutes, according to scientists behind a new €3.8 million project.

Molecular technology company GNA Biosolutions GmbH and its project partners announced the launch of PITBUL, a European Commission funded international research project aimed at developing a tuberculosis (TB) diagnostic platform to be utilized at the Point of Care.

The PITBUL project includes international partners from academic institutions, hospitals, research institutes and companies, which will collaborate to develop an ultrafast test that can detect TB infection in minutes rather than hours, as with current molecular TB tests. Project partners include the Dodoma Regional Referral Hospital in Tanzania, the National Institute for Infectious diseases “L. Spallanzani” (based in Rome, Italy), the University of Latvia and the Riga East University Hospital, Fraunhofer IMM (Mainz, Germany), TATAA Biocenter, and MultiD Analyses AB (both in Göteborg, Sweden). GNA Biosolutions is serving as the project coordinator.

Traditional DNA tests for TB can take up to several hours to deliver a diagnosis. The PITBUL ultrafast TB test will be based on Pulse Controlled Amplification (PCA), a novel platform technology developed by GNA Biosolutions. The PITBUL ultrafast TB test aims to make DNA-based diagnosis of TB possible in just a few minutes. “Tuberculosis is a global public health threat, particularly with multi-drug resistant TB strains on the rise,” said GNA Biosolutions Managing Director Lars Ullerich. “We are excited to have a world -renowned team assembled so that together we can take on the challenge of making an extremely fast, cost-effective and easy-to-use TB test a reality.”

The European Commission’s Horizon 2020 program, the EU’s largest Research and Innovation program, has awarded PITBUL 3.8 million Euros for the duration of the project, which is expected to conclude in 2020. To commemorate this year’s World TB Day, the PITBUL team today launched a website which will provide additional details and news about this publicly funded research project.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    HP Health Solutions Germany GmbH. (2024, September 04). GNA Biosolutions and project partners launch new research project to develop TB diagnostic platform for POC applications. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/news/20180420/GNA-Biosolutions-and-project-partners-launch-new-research-project-to-develop-TB-diagnostic-platform-for-POC-applications.aspx.

  • MLA

    HP Health Solutions Germany GmbH. "GNA Biosolutions and project partners launch new research project to develop TB diagnostic platform for POC applications". News-Medical. 21 November 2024. <https://www.news-medical.net/news/20180420/GNA-Biosolutions-and-project-partners-launch-new-research-project-to-develop-TB-diagnostic-platform-for-POC-applications.aspx>.

  • Chicago

    HP Health Solutions Germany GmbH. "GNA Biosolutions and project partners launch new research project to develop TB diagnostic platform for POC applications". News-Medical. https://www.news-medical.net/news/20180420/GNA-Biosolutions-and-project-partners-launch-new-research-project-to-develop-TB-diagnostic-platform-for-POC-applications.aspx. (accessed November 21, 2024).

  • Harvard

    HP Health Solutions Germany GmbH. 2024. GNA Biosolutions and project partners launch new research project to develop TB diagnostic platform for POC applications. News-Medical, viewed 21 November 2024, https://www.news-medical.net/news/20180420/GNA-Biosolutions-and-project-partners-launch-new-research-project-to-develop-TB-diagnostic-platform-for-POC-applications.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.